---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-005398"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2024-02-08T23:59:59+00:00"
generated_at: "2026-06-06T05:57:27.346132+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics announces three US patents for fibroblast technology

## Summary
- Patent 11,717,596 (Sevrain): Methods for cartilage repair using in vivo bioreactor.
- Patent 11,732,239 (O'Heeron): Treatment of disc degenerative disease with fibroblast conditioned media.
- Patent 11,819,555 (O'Heeron): Gene therapy for regeneration of chondrocytes or cartilage-type cells.
- Company now holds 150+ patents issued and pending, reinforcing its IP portfolio.

## SEC filing metadata
- accession: 0001493152-24-005398
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2024-02-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000149315224005398/0001493152-24-005398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000149315224005398/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-005398
- JSON: https://secwatch.observer/filing/0001493152-24-005398.json
- Plain text: https://secwatch.observer/filing/0001493152-24-005398.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.